AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04421365 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: neurofeedback brain-computer interface (BCI)
Description: The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
Study NCT06245486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crispact®
Description: Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247
Study NCT06245486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06387927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercise program
Description: Patients in group B were taught the core stability exercise in the first visit they received Arabic printed booklet for exercise description repetitions with diagrams in addition to Arabic illustration videos, they received a weekly telephone call to ensure their compliance to the exercise \& motivation.
Study NCT06387927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the core stability exercise
Description: supervised conventional core stability exercise
Study NCT06505616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compared the trombogenicity of the Solacea dialyzer with synthetic dialyzers after progressively decreasing heparin until discontinuing it
Description: The duration of the study was four weeks, carried out in two phases. After screening, patients were randomized to be dialyzed with the Solacea™ hemodialyzer versus the usual hemodialyzer, which in all cases had to be a synthetic membrane. In both arms, heparin was progressively decreased until it was discontinued. Afterwards the patients were crossed over to the other arm.
Study NCT06299930 — intervention group
Intervention type: PROCEDURE
Intervention: Neoadjuvant chemotherapy
Description: Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy
Study NCT06299930 — intervention group
Intervention type: PROCEDURE
Intervention: Adjuvant chemotherapy
Description: Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy
Study NCT05479916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycated milk protein
Description: 40 grams of protein dissolved in 600 mL of water
Study NCT05479916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High glycated milk protein
Description: 40 grams of protein dissolved in 600 mL of water
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg IV
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg IV
Study NCT05109429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Cue-induced Craving
Description: For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
Study NCT06229990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: After taking furosemide at 1.5 mg/kg intravenously, if the urine output exceeds 200 mL within 2 hours, the patients are going to withhold CRRT. But if there is no response, the titration of furosemide to 2.5 mg/kg and 3.5 mg/kg every 6 hours is scheduled according to the urine output >200 mL in 2 hours (not exceeding 250 mg).
Study NCT06279962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The intervention is being assigned to one of the 8 different versions of the survey vignette.
Study NCT05109429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Opioid Cue-induced Craving
Description: For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
Study NCT05109429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual and Tactile Opioid Cue-induced Craving
Description: For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
Study NCT06024109 — intervention group
Intervention type: DEVICE
Intervention: Closure of the Vaginal Cuff after Total Hysterectomy
Description: Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
Study NCT05031299 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
Study NCT05031299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-promotion application for self-management
Description: Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
Study NCT05031299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearables and devices
Description: Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
Study NCT04821921 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Care as usual
Study NCT05645107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xembify
Description: SC infusion pump
Study NCT05645107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC infusion pump
Study NCT06471452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interaktor
Description: In the app (Interaktor), the patients will report frequency and distress on common symptoms and concerns.~Free text comments will also be possible to make to cover the patients' other potential needs. Information about the concerns will be included in the app containing; a) general information about why they have the side effects and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents, web pages or YouTube videos.~Supportive Care delivered from a study-specific nurse. During the health dialogues with a nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and needs and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patient's journal.
Study NCT06224140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Anticoagulation
Description: Conventional dialysis with heparin as anticoagulant treatment
Study NCT06224140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Anticoagulation Procedure (RAP)
Description: Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.
Study NCT05812963 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI group
Description: In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
Study NCT05812963 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FFR-guided PCI group
Description: In FFR-guided PCI group, FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis >90%, we will judge FFR value of ≤0.80.
Study NCT05626140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 50 MG Oral Tablet [Vimpat]
Description: Oral tablet lacosamide is a 3rd generation anti convulsant drug. it is given in a dose of 50 mg 12 hourly for 15 days. It has a longer half life than the other two drugs in comparison and fewer drug interactions as it doesnot interact with the hepatic cytochrome enzymes.hence it is seen to have better pharmacokinetics and pharmacodynamics than the other drugs in study
Study NCT05626140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Phosphate
Description: Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
Study NCT05626140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
Study NCT05626140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
Study NCT05265390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adolescents watching an informational video
Description: In the information video; The materials used during the PCR test, how long the process will take, how the sample will be taken, why healthcare professionals wear personal protective equipment, and what adolescents should do are included.
Study NCT05626140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac Sodium
Description: Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
Study NCT04997161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Description: Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
Study NCT04731194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance-based financial incentive program
Description: 1. Enhance policy awareness through verbal communication with patients, distributing picture-rich fliers to patients, and putting up large posters in public places of the villages.~2. Support patients' registration in the reimbursement system~3. Follow-up patients after the first, third, and sixth months after the start of the study, measuring blood pressure and blood glucose level. Encourage patients to purchase medications from public institutions and to take their medications on time.~4. Receive financial incentives based on performance in the amount of 3 RMB per patient enrolled (first month) and 5 RMB per patient (at third and sixth month) buying medications with reimbursement from the policy.
Study NCT04997161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced dietary advice
Description: Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.
Study NCT05007418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-1492
Description: Anti-CD38 A2 KOKI DAR T cells
Study NCT04997161 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard dietary advice including K+ restriction.
Description: Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.
Study NCT05827328 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observe the 30-day mortality and 30-day morbidity.
Study NCT04678362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib + Avelumab
Description: Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
Study NCT04807608 — intervention group
Intervention type: OTHER
Intervention: Usability Assessment
Description: A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.
Study NCT05399589 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: use on1 abutment instead of healing cap in test group
Description: We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.
Study NCT05399589 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: use healing cap in control group
Description: use healing cap in control group
Study NCT05199636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dragon fruit product
Description: Frozen dragon fruit based beverage
Study NCT05790018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREGNANT PILLOW
Description: First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
Study NCT06652412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrafractionated RT and CGA Guided systemic treatment.
Description: in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.
Study NCT06652412 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: data prospectively collected
Description: in cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.
Study NCT06652412 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrafractionated Radiotherapy
Description: 1Fx every 3 or 4weeks
Study NCT06652412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg q3w
Study NCT06652412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-Fluorouracil or capecitabine
Study NCT06652412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed
Study NCT06652412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin
Study NCT06652412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: irinotecan
Study NCT06380036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video assisted fistula tract surgery
Description: in one group pt recieved VAAFTS
Study NCT06659211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalisation-Based Therapy
Description: MBT is conducted according to the treatment manual developed by Bateman \&amp; Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.
Study NCT06659211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system, and the usual treatment would not be the usual treatment currently provided.
Study NCT06221943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Naturalistic Developmental Behavioral Intervention
Description: Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in a group setting.
Study NCT06221943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-on-one Naturalistic Developmental Behavioral Intervention
Description: Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in an one-on-one setting
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 25mg/m2 IV
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 25mg/m2 IV
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine 6mg/m2 IV
Study NCT06221943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASD Diagnosis
Description: Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
Study NCT06221943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASD Diagnosis
Description: Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
Study NCT06245304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dual chamber Medtronic pacemaker implantation.
Description: All patients will undergo a dual chamber Medtronic pacemaker implantation meeting approved indications for pacemaker implantation per Centers for Medicare \& Medicaid Services (CMS) guidelines.~Pacemaker Model: Azure XT W1DR01. Right ventricular lead model: Medtronic 3830.
Study NCT06245304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DDD-50 pacing program
Description: This device programming attempts to increase the amount of ventricular pacing via the Medtronic 3830 lead. Since the enrolled patients have a prolonged PR interval, this programming attempts to synchronic atrial and ventricular contractions.
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: Vinblastine 6mg/m2 IV
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine 375mg/m2 IV
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine 375mg/m2 IV
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin 1.8 mg/kg IV
Study NCT05404945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin 1.8 mg/kg IV
Study NCT06112080 — intervention group
Intervention type: DEVICE
Intervention: RESP™ Biosensor
Description: The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
Study NCT06245304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AAI-DDD 50 pacing program
Description: This device programming attempts to encourage native conduction and minimize ventricular pacing via the Medtronic 3830 lead. This programming attempts to minimize ventricular pacing, which has been associated with worse outcomes by causing ventricular dyssynchrony between the left and right ventricles.
Study NCT05097560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.